Monday, April 22, 2013

Intas launches Rituxan biosimilar in India under the brand name Mabtas

There is competition coming in for Dr. Reddy's Reditux, which so far has dominated the Rituxan biosimilar market. Intas pharma has announced the launch of biosimilar copy of Rituxan under the brand name Mabtas in India. Intas Pharma's subsidary Intas Bio-Pharma is already selling  biosimilars, which include pegfligrastim, rHu G–CSF, Erythropoietin and interferon alfa2b. 


Dr. Reddy launched Reditux in India in April 2007 at ~40% discount to the original price in India and resulted in a 10-fold market expansion for the product.  In 2010–11, domestic revenues from Reditux grew 75% making the product the fourth-largest brand in Dr Reddy’s portfolio.  DRL generated US$26m for its biosimilars business as a whole, and announced in 2012 its plan to launch its biosimilar Reditux in Europe 

Mabtas is a biosimilar version of Rituximab, competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. Such diseases include many forms of lymphoma, leukemia, and transplant rejection, autoimmune disorders such as Rheumatoid Arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). Mabtas may be used alone or in combination with other chemotherapy medicines to treat Non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Enter your email address:


Delivered by FeedBurner